A Phase III, Randomized, Double-Blind, Active-Controlled Non-Inferiority Trial Evaluating the Immunogenicity and Safety of Gardisun, a Quadrivalent Human Papillomavirus Vaccine, Compared with Gardasil® in Healthy Volunteers Aged 15–35 Years
Vaccines · 18.06.2026 · 14 (6) · 540
DOI: 10.3390/vaccines14060540 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 18.06.2026. Verfasst von Erfan Pakatchian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biosunpharmed Company, Tehran 14369335359, Iran. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Human papillomavirus (HPV) infection is the leading cause of cervical cancer and is associated with several anogenital and oropharyngeal malignancies. Although licensed HPV vaccines are highly effective, access remains limited in many low- and middle-income countries due to cost, supply shortages, and implementation barriers. In this study, we evaluated the immunogenicity and safety of Gardisun, a newly developed quadrivalent prophylactic HPV vaccine, compared with Gardasil®.
Methods
This Phase III randomized, double-blind, active-controlled, parallel-group non-inferiority trial enrolled 450 healthy participants stratified by sex and randomized (1:1) to receive three 0.5 mL intramuscular doses of Gardisun or Gardasil® on Days 0, 60, and 180. Participants were followed through to Day 210. The primary endpoint was the geometric mean titer (GMT) of antibodies against HPV types 6, 11, 16, and 18 one month after the administration of the third dose. Non-inferiority was defined as the lower bound of the 95% confidence interval (CI) for the GMT ratio exceeding 0.67. Safety was assessed through adverse event monitoring.
Results
Of the 450 randomized participants, 422 completed the Month 7 visit and 429 received all three doses. Both vaccines induced antibody responses and seroconversion rates for all HPV types. The primary analysis met the non-inferiority criterion for HPV-6, while prespecified sensitivity analyses supported the existence of non-inferiority across all evaluated HPV types. Most adverse events were mild and transient, with no vaccine-related serious adverse events reported.
Conclusions
Gardisun demonstrated robust immunogenicity and a safety profile comparable to that of Gardasil®, supporting its potential as an accessible alternative quadrivalent HPV vaccine for broader vaccination programs in resource-limited settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biosunpharmed Company, Tehran 14369335359, Iran.
- Department of Infectious and Tropical Diseases, Iranian Research Center for HIV/AIDS (IRCHA), School of Medicine, Tehran University of Medical Sciences, Tehran 1416753955, Iran.
ORCID-Profile: Zahra Naderi Saffar
Zitieren
APA
Pakatchian, E., Mohraz, M., Taghavian, M., Javadimehr, B., Mohammadi Barzelighi, H., Teymoori-Rad, M., Ghodsi, M., & Saffar, Z. N. (2026). A Phase III, Randomized, Double-Blind, Active-Controlled Non-Inferiority Trial Evaluating the Immunogenicity and Safety of Gardisun, a Quadrivalent Human Papillomavirus Vaccine, Compared with Gardasil® in Healthy Volunteers Aged 15–35 Years. Vaccines, 14(6), 540. https://doi.org/10.3390/vaccines14060540
Vancouver
Pakatchian E, Mohraz M, Taghavian M, Javadimehr B, Mohammadi Barzelighi H, Teymoori-Rad M, et al. A Phase III, Randomized, Double-Blind, Active-Controlled Non-Inferiority Trial Evaluating the Immunogenicity and Safety of Gardisun, a Quadrivalent Human Papillomavirus Vaccine, Compared with Gardasil® in Healthy Volunteers Aged 15–35 Years. Vaccines. 2026;14(6):540. doi:10.3390/vaccines14060540
BibTeX
@article{Pakatchian2026,
author = {Pakatchian, Erfan and Mohraz, Minoo and Taghavian, Mohammad and Javadimehr, Babak and Mohammadi Barzelighi, Hajar and Teymoori-Rad, Majid and Ghodsi, Mehrdad and Saffar, Zahra Naderi},
title = {A Phase III, Randomized, Double-Blind, Active-Controlled Non-Inferiority Trial Evaluating the Immunogenicity and Safety of Gardisun, a Quadrivalent Human Papillomavirus Vaccine, Compared with Gardasil® in Healthy Volunteers Aged 15–35 Years},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {6},
pages = {540},
doi = {10.3390/vaccines14060540}
}
EUVIMED